Applied Therapeutics Net Worth
Applied Therapeutics Net Worth Breakdown | APLT |
Applied Therapeutics Net Worth Analysis
Applied Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Applied Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Applied Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Applied Therapeutics' net worth analysis. One common approach is to calculate Applied Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Applied Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Applied Therapeutics' net worth. This approach calculates the present value of Applied Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Applied Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Applied Therapeutics' net worth. This involves comparing Applied Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Applied Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Applied Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Applied Therapeutics' net worth research are outlined below:
| Applied Therapeutics generated a negative expected return over the last 90 days | |
| Applied Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 9.99 M. Net Loss for the year was (119.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Applied Therapeutics currently holds about 67.72 M in cash with (55.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.41. | |
| Applied Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: FDA Rejects Applied Therapeutics NDA for Govorestat, Citing Flaws Shares Plunge 76 |
Applied Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Applied Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Applied Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Applied Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Applied Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Applied Therapeutics backward and forwards among themselves. Applied Therapeutics' institutional investor refers to the entity that pools money to purchase Applied Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 2.8 M | Tang Capital Management Llc | 2024-09-30 | 2.7 M | Deutsche Bank Ag | 2024-06-30 | 2.3 M | Geode Capital Management, Llc | 2024-09-30 | 2.1 M | State Street Corp | 2024-06-30 | 1.7 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.6 M | Stempoint Capital Lp | 2024-09-30 | 1.6 M | Opaleye Management Inc | 2024-09-30 | 1.3 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.3 M | Vr Adviser, Llc | 2024-09-30 | 9.8 M | Perceptive Advisors Llc | 2024-09-30 | 8 M |
Follow Applied Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 236.2 M.Market Cap |
|
Project Applied Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.18) | (2.29) | |
| Return On Capital Employed | 3.95 | 4.14 | |
| Return On Assets | (2.18) | (2.29) | |
| Return On Equity | 6.98 | 7.33 |
When accessing Applied Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Applied Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Applied Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Applied Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Applied Therapeutics. Check Applied Therapeutics' Beneish M Score to see the likelihood of Applied Therapeutics' management manipulating its earnings.
Evaluate Applied Therapeutics' management efficiency
Applied Therapeutics has return on total asset (ROA) of (0.7601) % which means that it has lost $0.7601 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7339) %, meaning that it created substantial loss on money invested by shareholders. Applied Therapeutics' management efficiency ratios could be used to measure how well Applied Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Applied Therapeutics' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 7.33 in 2024, whereas Return On Tangible Assets are likely to drop (2.29) in 2024. At this time, Applied Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 56.5 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 681.3 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.20) | (0.19) | |
| Tangible Book Value Per Share | (0.20) | (0.19) | |
| Enterprise Value Over EBITDA | (3.61) | (3.43) | |
| Price Book Value Ratio | (16.46) | (15.64) | |
| Enterprise Value Multiple | (3.61) | (3.43) | |
| Price Fair Value | (16.46) | (15.64) | |
| Enterprise Value | 233.1 M | 152.4 M |
The decision-making processes within Applied Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 62.3697 | Revenue -212 K | Quarterly Revenue Growth (0.98) | Revenue Per Share (0) | Return On Equity (4.73) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Applied Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Applied Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Applied Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Applied Therapeutics Corporate Filings
8K | 27th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify |
Applied Therapeutics Earnings per Share Projection vs Actual
Applied Therapeutics Corporate Management
| Riccardo MD | Chief Officer | Profile | |
| Chids Mahadevan | Sr Officer | Profile | |
| Steven Ortega | Chief Officer | Profile | |
| Catherine Thorpe | Chief Officer | Profile | |
| Adam Hansard | Chief Officer | Profile |
Already Invested in Applied Therapeutics?
The danger of trading Applied Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Applied Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Applied Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Applied Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.